EChENIE NEYTROPENII U ONKOLOGIChESKIKh BOL'NYKh
- Authors: Abramov M.E.1, Darenskaya A.D.1
-
Affiliations:
- Issue: No 8 (2012)
- Pages: 45-50
- Section: Articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/279560
- ID: 279560
Cite item
Open Access
Access granted
Abstract
Neutropenia is one of the major side effects of cytostatic treatment of tumor diseases, contributing to the development of infectious complications. Prolonged neutropenia often does not allow chemotherapy as planned, and can lead to chemotherapy dose reduction, which ultimately reduces the effectiveness of antineoplastic therapy. Therefore, carefully evaluation of myelotoxic potential of modern chemotherapy regimens and identification of patients at high risk of febrile neutropenia, in need of prophylactic colony-stimulating factor, are required. The success of the treatment of febrile neutropenia depends on early detection of possible infection and early treatment.
Full Text
About the authors
Mikhail Evgen'evich Abramov
Email: mikhailabramov@newmail.ru
Anna Dmitrievna Darenskaya
References
- Crawford J, Althaus D, et al. National Comprehensive Cancer Network. Myeloid growth factors clinical practice guidelines in oncology. J Nat Compreh Cancer Network 2005;3:540-55.
- ASCO Recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. J Clin Oncol 1994;12:2471-250.
- Zielinski CC, Awada A, Cameron DA, et al. The impact of new European Organisation for Research and Treatment of Cancer guidelines on the use of granulocyte colony-stimulating factor on the management of breast cancer patients. Eur J Cancer 2008;44: 353-65.
- Vogel CL, Wojtukiewicz MZ, Carroll RR, et al. First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: a multicenter, double-blind, placebo-controlled phase III study. J Clin Oncol 2005;23:1178-84.
- Timmer-Bonte JN, de Boo TM, Smith HJ, et al. Prevention of chemotherapyinduced febrile neutropenia by prophylactic antibiotics plus or minus granulocyte colony-stimulating factor in small cell lung cancer: a Dutch randomized phase III study. J Clin Oncol 2005;23:7974-84.
- Yoshida M, Ohno R. Antimicrobial prophylaxis in febrile neutropenia. Clin Infect Dis 2004;39 (1):65-7.
- Cullen M, Steven N, Billingham L, et al. Antibacterial prophylaxis after chemotherapy for solid tumours and lymphomas. N Engl J Med 2005;353:988-98.
- Минимальные клинические рекомендации Европейского общества медицинской онкологии (ESMO). М., 2010. C. 375-91.
- Klastersky J, Paesmans M, Rubenstein E B et al. The Multinational Association for Supportive Care in Cancer risk index: a multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol 2000; 18:3038-51.
- Innes H, Lim SL, Hall A, et al. Management of febrile neutropenia in solid tumours and lymphomas using the Multinational Association for Supportive Care in Cancer (MASCC) risk index: feasibility and safety in routine clinical practice. Supp Care Cancer 2008;16: 485-491.
- Vidal L, Paul M, Ben Dor I, et al. Oral versus intravenous antibiotic treatment for febrile neutropenia in cancer patients: a systematic review and meta-analysis of randomized trials. J Antimicrob Chemother 2004;54:29-37.
- Kovacs J, Masour H. Evolving health effects of Pneumocystis: one hundred years of progress of diagnosis and treatment. JAMA 2009;301:2578-85.
- Wolf H-H, Leithauser M, Maschmeyer G, et al. Central venous catheter-related infections in hematology and oncology. Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Ann Hematol 2008;87:863-76.
- Raad I, Kassar R, Dany G, et al. Management of the catheter in documented catheter-related coagulase-negative staphylococcal bacteremia: remove or retain? Clin Infect Dis 2009;49:1187-194.
- Kim SH, Kang CI, Kim HB, et al. Outcomes of hickman catheter salvage in febrile neutropenic cancer patients with Staphylococcus aureus bacteremia. Infect Control Hosp Epidemiol 2003;24:897-904.
- Walsh TJ, Teppler H, Donowitz GR, et al. Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. N Engl J Med 2004;351:1391-402.
- Herbrecht R, Denning DW, Patterson TF, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002;347:408-15.
- Dockrell DH. Salvage therapy for invasive aspergillosis. J Antimicrob Chemother 2008;61:41-4.
- Schmutzhard E, Williams KJ, Vukmirovits G, et al. A randomised comparison of meropenem with cefotaxime or ceftriaxone for the treatment of bacterial meningitis in adults. Meropenem Meningitis Study Group. J Antimicrob Chemother 1995;36:85-97.
Supplementary files
